Pre-made Vofatamab biosimilar ( Whole mAb, anti-FGFR3 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-626
Anti-FGFR3 therapeutic antibody (Pre-made Vofatamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vofatamab (B-701, Rainier Therapeutics) is an antibody that targets fibroblast growth factor receptor 3 (FGFR3), an established driver of bladder cancer and other malignancies.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-FGFR3 therapeutic antibody (Pre-made Vofatamab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||4wv1:BA:ED/3grw:HL|
|Companies||BioClin Therapeutics;Rainier Therapeutics|
|Conditions Active||Urogenital cancer|
|Conditions Discontinued||Multiple myeloma;Solid tumours;Achondroplasia|